6/11/2010

Novartis has received FDA panel support for the approval of Gilenia, its oral drug for relapsing-remitting multiple sclerosis. The advisory committee also recommended that Novartis investigate the effectiveness of lower doses of the treatment.

Full Story:
WebMD

Related Summaries